BUSINESS: Obseva Announces Appointment Of Stephanie Brown To Its Board Of Directors
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: Obseva Announces Appointment Of Stephanie Brown To Its Board Of Directors

November 22, 2021 01:00 ET | Source: ObsEva SA Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Stephanie Brown has been selected…

BUSINESS: Positive Phase-IIb-Ergebnisse Bei Zweitlinienbehandlung Von Melanomen
| | | | | | | | | | | | | | |

BUSINESS: Positive Phase-IIb-Ergebnisse Bei Zweitlinienbehandlung Von Melanomen

November 13, 2021 15:52 ET | Source: Highlight Therapeutics Highlight Therapeutics gibt auf der SITC positive vorläufige Ergebnisse der Phase-IIb-Studie zu BO-112 + Anti-PD1 bei Melanompatienten mit bestätigter Progression nach Anti-PD-1-Erstlinienbehandlung bekannt Bahnbrechende Krebsbehandlung zeigt erstklassiges Potenzial zur Öffnung des Marktes für Zweitlinien-Immuntherapien für Anti-PD-1-resistente Patienten BO-112 zeigt das Potenzial als beste Therapie seiner Klasse…

BUSINESS: Resultats Positifs De La Phase 2b Pour Le Melanome En 2e Ligne
| | | | | | | | | | | | | | | | |

BUSINESS: Resultats Positifs De La Phase 2b Pour Le Melanome En 2e Ligne

November 13, 2021 15:52 ET | Source: Highlight Therapeutics Highlight Therapeutics annonce les résultats préliminaires positifs de l’étude de phase 2b sur le BO-112 + anti-PD1 chez des patients atteints de mélanome dont la maladie avait progressé avec l’anti-PD1 de manière confirmée lors de la SITC Un traitement révolutionnaire contre le cancer montre un potentiel…

BUSINESS: Intensity Therapeutics Reports Promising Overall Survivability Results Using INT230-6 In Monotherapy Or In Combination With Pembrolizumab Or Ipilimumab To Treat Solid Tumors At The Society For Immunotherapy Of Cancer’s 36th Annual Meeting
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: Intensity Therapeutics Reports Promising Overall Survivability Results Using INT230-6 In Monotherapy Or In Combination With Pembrolizumab Or Ipilimumab To Treat Solid Tumors At The Society For Immunotherapy Of Cancer’s 36th Annual Meeting

WESTPORT, Conn., Nov. 13, 2021 /PRNewswire/ — Intensity Therapeutics, Inc. (“Intensity”), a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the Company made two presentations on novel lead asset, INT230-6, at the Society for Immunotherapy…

BUSINESS: $18.9 Billion UV-C LED Market – Global Growth, Drivers, COVID-19 Impact And Forecasts To 2030
| | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: $18.9 Billion UV-C LED Market – Global Growth, Drivers, COVID-19 Impact And Forecasts To 2030

November 12, 2021 07:18 ET | Source: Research and Markets Dublin, Nov. 12, 2021 (GLOBE NEWSWIRE) — The “UV-C LED Market by Application: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering. The global UV-C LED market size was valued at $208.3 million in 2020 and is projected to reach…

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: MSCI Equity Indexes Nov 2021 Index Review

LONDON–(BUSINESS WIRE)–MSCI Inc. (NYSE:MSCI), a leading provider of research-based indexes and analytics, announced the results of the November 2021 Semi-Annual Index Review for the MSCI Equity Indexes – including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Global Value and Growth Indexes, the MSCI Frontier Markets, and MSCI…

FRONT PAGES: A Closer Look At Unexamined Interactions Could Enhance Drug Purification Process
| | | | | | | | | | | | | | | | |

FRONT PAGES: A Closer Look At Unexamined Interactions Could Enhance Drug Purification Process

Newswise — TROY, N.Y. — The process of purifying biopharmaceutical drugs remains a costly and time-consuming challenge. A deeper understanding of how unwanted elements within biomanufactured proteins bind to the molecules developed to remove them could help researchers make purity processes more efficient, more complex, and increasingly scalable.In research published in Langmuir, a team led…

BUSINESS: A2 Bio Highlights Program Updates In Two Presentations At SITC 2021
| | | | | | | | | | | | | | | | | | | | |

BUSINESS: A2 Bio Highlights Program Updates In Two Presentations At SITC 2021

AGOURA HILLS, Calif.–(BUSINESS WIRE)–A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid tumors. A2 Bio will make two presentations at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place virtually and in person on Nov. 10–14, 2021 at the Walter…

BUSINESS: New To The Street T.V. Announces Four Corporate Interviews On Its 259th T.V Show, Airing On Fox Business Network, Tonight, Monday, October 25, 2021, At 10:30 PM P.T. And The 260th T.V. Show Airing Tomorrow Night, Tuesday, October 26, 2021, At 10:30 PM PT
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: New To The Street T.V. Announces Four Corporate Interviews On Its 259th T.V Show, Airing On Fox Business Network, Tonight, Monday, October 25, 2021, At 10:30 PM P.T. And The 260th T.V. Show Airing Tomorrow Night, Tuesday, October 26, 2021, At 10:30 PM PT

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) — FMW Media’s New to The Street T.V. announces the broadcastings of its nationally syndicated shows tonight, Monday, November 01, 2021, at 10:30 PM PT and tomorrow, Tuesday night, November 02, 2021, at 10:30 PM PT on Fox Business Network. New to The Street’s 259th T.V. show, airing…

BUSINESS: Merck Grants To Friends Of Puerto Rico In Order To Create STEM Entrepreneurs
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: Merck Grants To Friends Of Puerto Rico In Order To Create STEM Entrepreneurs

Aguadilla, PR, October 29, 2021 –(PR.com)– Friends of Puerto Rico, a non-profit organization focused on developing entrepreneurial initiatives for at-risk children, received a $50,000 grant from Merck, known as MSD outside the United States and Canada, to support SEEDS, a K-12 STEM-based youth entrepreneurship program.The grant project is part of the Neighbor of Choice Program, designed…

INDIA NEWS: India Monoclonal Antibodies Markets Analysis, Forecast & Opportunities, 2016-2020 & 2021-2026
| | | | | | | | | | | | | | | | | | | | | |

INDIA NEWS: India Monoclonal Antibodies Markets Analysis, Forecast & Opportunities, 2016-2020 & 2021-2026

INDIA NEWS: DUBLIN–(BUSINESS WIRE)–The “India Monoclonal Antibodies Market, By Type (Murine, Chimeric, Humanized, Human), By Application (Cancer, Cardiac/Cardiovascular, Neurological, Others), By Production, By Biomanufacturing, By End Users, By Region, Forecast & Opportunities, FY2026” report has been added to ResearchAndMarkets.com’s offering. The monoclonal antibody market in India is expected to expand at a steady pace during…

BUSINESS: Coretec Group Announces Promotions For Key Team Members
| | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: Coretec Group Announces Promotions For Key Team Members

ANN ARBOR, Mich.–(BUSINESS WIRE)–The Coretec Group, Inc., (OTCQB: CRTG), developers of engineered silicon and 3D volumetric displays, is pleased to announce the promotions of Dr. Michelle Tokarz to Vice President of Partnerships & Innovation and Dr. Ramez Elgammal to Chief Technology Officer. As The Coretec Group moves forward in the development of multiple technologies across…

BUSINESS: The Squamous Non-Small Cell Lung Cancer Market Is Projected To Grow At A CAGR Of 10.8% Till 2030, Claims Roots Analysis
| | | | | | | | | | | | | | | | | |

BUSINESS: The Squamous Non-Small Cell Lung Cancer Market Is Projected To Grow At A CAGR Of 10.8% Till 2030, Claims Roots Analysis

Advances in molecular biology and tumor immunology have enabled the development of NSCLC targeting therapies, which have the ability to impede cancer growth by altering chemical reactions associated with oncogenic driver mutations October 26, 2021 09:15 ET | Source: Roots Analysis London, Oct. 26, 2021 (GLOBE NEWSWIRE) — Roots Analysis has announced the addition of…

BUSINESS: The Pre-Filled Syringes And Injectable Dispensers Conference 2022
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: The Pre-Filled Syringes And Injectable Dispensers Conference 2022

London, United Kingdom, October 24, 2021 –(PR.com)– The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products. This year’s conference will explore the exciting advances in the combination product delivery space including insights into how the industry…

BUSINESS: MSD Teams Up With Friends Of Cancer Patients And Emirates Oncology Society For The EMBRACE Campaign
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: MSD Teams Up With Friends Of Cancer Patients And Emirates Oncology Society For The EMBRACE Campaign

DUBAI, UAE, Oct. 24, 2021 /PRNewswire/ — MSD, a leading global biopharmaceutical company, together with Emirates Oncology Society and Friends of Cancer Patients (FOCP), has announced the launch of EMBRACE, a campaign to mark Breast Cancer Awareness Month this October. The partners will work together throughout the month to roll out a series of offline and…

FRONT PAGE: Targeted Drug Shows Activity Against Brain Metastases In Kidney Cancer
| | | | | | | | | | | | | | | | | | | | | | | | | |

FRONT PAGE: Targeted Drug Shows Activity Against Brain Metastases In Kidney Cancer

Cancer drugs have shown little benefit in patients with kidney cancer metastatic to the brainA study of cabozantinib, a drug that hits multiple targets on tumors, has shown considerable activity against brain metastases in kidney cancerNewswise — BOSTON – A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a…

UK NEWS: COVID-19: UK agrees to two antiviral drugs in order to combat the coronavirus surge this season
| | | | | | | | | | | | | | | |

UK NEWS: COVID-19: UK agrees to two antiviral drugs in order to combat the coronavirus surge this season

– Health Secretary Sajid Javid has hailed two possible new additions to the UK’s “armoury of life-saving measures” to tackle COVID-19. The government’s antivirals taskforce has struck deals for two new coronavirus treatments, which – if they are approved by the medicines regulator – are expected to be given to those most vulnerable to COVID-19.…

FOOD SAFETY: IAFP requests nominations for the 2022 conference and annual meeting
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

FOOD SAFETY: IAFP requests nominations for the 2022 conference and annual meeting

. The International Association for Food Protection invites nominations for the awards that will be presented at this years annual conference. The deadline for submissions is Tuesday, Feb. 15, 2022. The awards will be presented at IAFP’s annual conference is set for July 31-Aug. 3 next year in Pittsburgh, PA. The categories include the Black…

ASIA NEWS: Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Get positive EU CHMP opinions for LENVIMA, (lenvatinib), and KEYTRUDA in two different types of cancer
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

ASIA NEWS: Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Get positive EU CHMP opinions for LENVIMA, (lenvatinib), and KEYTRUDA in two different types of cancer

TOKYO and KENILWORTH, N.J., Oct 18, 2021 – (JCN Newswire) – Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted positive opinions recommending approval of the combination…

BUSINESS: Global Protein Therapeutics Market (21-2026) – Industry Trends And Size, Growth, Opportunity, And Forecasts
| | | | | | | | | | | | | | | | | | | | | |

BUSINESS: Global Protein Therapeutics Market (21-2026) – Industry Trends And Size, Growth, Opportunity, And Forecasts

DUBLIN, Oct. 18, 2021 /PRNewswire/ — The “Protein Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. The global protein therapeutics market exhibited moderate growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of around 6% during 2021-2026. Keeping in…

End of content

End of content